How many pregnant women receive unnecessary anti-D prophylaxis?



PrenatalDetect RHD

from Devyser Genomic Laboratories

Devyser Genomic Laboratories offers a proven, highly sensitive and accurate test¹ for non-invasive screening of fetal Rhesus D (RhD).

40% of Rh-negative mothers are carrying an Rh-negative fetus and would be exposed to unnecessary treatment with potential risks.²

With our test results, physicians can ensure that only mothers that need anti-D prophylaxis, receive it.

Personalized treatment

Empowers patients to decide on the testing and treatment they want during pregnancy.

Non-invasive


Sample collection from gestation week 10 and a single EDTA blood tube is all that is needed.

Saves time


Avoid multiple visits to the care provider for injections.



Non-invasive blood draw



PrenatalDetect RHD test



Reduce unnecessary prophylaxis






^{1.} Laboratory-developed test 2. de Haas M, Finning K, Massey E, Roberts DJ. Anti-D prophylaxis: past, present and future. Transfus Med. 2014;24(1):1-7. doi:10.1111/tme.12099

State-of-the-art Prenatal Detect RHD test

Our Prenatal Detect RHD service process



Contact order@us.devyser.com to order



Devyser Genomic Laboratories

11660 Alpharetta Highway, Suite 700, Office 790 Roswell, GA 30076 +1 (877) 338-9737 laboratorysupport@us.devyser.com